Am J Psychiatry 1985; 142:28-33
Copyright © 1985 by American Psychiatric Association
Oral physostigmine treatment of patients with Alzheimer's disease
RC Mohs, BM Davis, CA Johns, AA Mathe, BS Greenwald, TB Horvath and KL Davis
Twelve patients with Alzheimer's disease received 0.0, 0.5, 1.0, 1.5, and
2.0 mg of oral physostigmine every 2 hours for 3-5 days; symptoms after
each dose were assessed with the Alzheimer's Disease Assessment Scale.
Placebo and the dose associated with the least severe symptoms were then
readministered for 3-5 days each. Of the 10 patients who completed the
study, three showed clinically significant improvement on the highest
physostigmine dose in both phases, four more were marginally improved in
both phases, and three had inconsistent responses to physostigmine.
Cortisol measures obtained during a sleep study suggest that patients whose
symptoms improved on physostigmine were those in whom oral physostigmine
enhanced central cholinergic activity.
This article has been cited by other articles:
|
|
|
|
 
C. K. Jones and H. E. Shannon
Muscarinic Cholinergic Modulation of Prepulse Inhibition of the Acoustic Startle Reflex
J. Pharmacol. Exp. Ther.,
September 1, 2000;
294(3):
1017 - 1023.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. H. van Dyck, P. Newhouse, W. E. Falk, J. A. Mattes, and for the Physostigmine Study Group
Extended-Release Physostigmine in Alzheimer Disease: A Multicenter, Double-blind, 12-Week Study With Dose Enrichment
Arch Gen Psychiatry,
February 1, 2000;
57(2):
157 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Davis, R. C. Mohs, D. Marin, D. P. Purohit, D. P. Perl, M. Lantz, G. Austin, and V. Haroutunian
Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
JAMA,
April 21, 1999;
281(15):
1401 - 1406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Thal, J. M. Ferguson, J. Mintzer, A. Raskin, and S. D. Targum
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease
Neurology,
April 1, 1999;
52(6):
1146 - 1146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Ye, J. X. Cai, L. M. Wang, and X. C. Tang
Improving Effects of Huperzine A on Spatial Working Memory in Aged Monkeys and Young Adult Monkeys with Experimental Cognitive Impairment
J. Pharmacol. Exp. Ther.,
February 1, 1999;
288(2):
814 - 819.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. L. Cummings and C. Back
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Am J Geriatr Psychiatry,
May 1, 1998;
6(2):
64S - 78.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N.H.P. Allen and A. Burns
The treatment of Alzheimer's disease
J Psychopharmacol,
January 1, 1995;
9(1):
43 - 56.
[PDF]
|
|
|
|
|
|
|
S. E. Molchan, A. M. Mellow, J. L. Hill, H. Weingartner, R. Martinez, B. Vitiello, and T. Sunderland
The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers
J Psychopharmacol,
January 1, 1992;
6(4):
489 - 500.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. E. Veroff, N. R. Cutler, J. J. Sramek, P. L. Prior, W. Mickelson, and J. K. Hartman
A New Assessment Tool for Neuropsychopharmacologic Research: The Computerized Neuropsychological Test Battery
J Geriatr Psychiatry Neurol,
October 1, 1991;
4(4):
211 - 217.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Notices
J Geriatr Psychiatry Neurol,
April 1, 1990;
3(2):
119 - 120.
[PDF]
|
|
|
|
|
|
|
M. A. Jenike
Alzheimer's Disease--What the Practicing Clinician Needs to Know
J Geriatr Psychiatry Neurol,
January 1, 1988;
1(1):
37 - 46.
[PDF]
|
|
|
|
|
|
|
G.C. Preston, C. Brazell, C. Ward, P. Broks, M. Traub, and S.M. Stahl
The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man
J Psychopharmacol,
January 1, 1988;
2(2):
67 - 79.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1985
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
